Chad Hall

Principal Scientist at Catalent

Speaker

Chad Hall is an accomplished life science leader with deep expertise in drug development, cell line engineering, and biologics manufacturing and experience spanning academia, biotech, big pharma, and CDMOs. He currently serves as a Principal Scientist at Catalent Biologics where he develops technologies for protein expression and manufacturing, including the GPEx® Lightning cell line development platform. Prior to Catalent, Chad led research at Amebagone focused on developing biologic treatments for bacterial diseases in plants and animals using Dictyostelium, a soil-dwelling amoeba. At Centrose he led efforts to elucidate the mechanism of action of their novel antibody drug conjugate technology. Chad completed a postdoc in the Oncology- Patient Tailoring Group at Eli Lilly where he helped determine the mechanism of action and identify biomarkers for targeted therapies in clinical development. Chad holds a PhD in Genetics from Baylor College of Medicine, where he identified a novel oncogene in ovarian cancer oncogene now being targeted in clinical trials, along with an MBA from Rice University and a BS in Genetics from the University of Wisconsin- Madison.